What to know first
Answer-first notes for searchers, readers, and clinician conversations.
The short version
FDA-approved GLP-1 products such as Wegovy, Ozempic, Zepbound, and Mounjaro have product-specific labels, manufacturing controls, adverse-event monitoring, and clinical-trial evidence tied to exact products and indications. Compounded or otherwise unapproved GLP-1 versions do not go through FDA review for safety, effectiveness, or quality before marketing.
Four categories readers should not blur together
Approved branded products are medicines with FDA-reviewed labeling for specific indications. Off-label use is a clinician-directed use of an approved product outside a labeled indication; it is not the same thing as an unapproved copy. Compounded products are not FDA-approved. FDA describes section 503A as applying to compounding by a licensed pharmacist within a state-licensed pharmacy or federal facility, or by a licensed physician, that is not a registered outsourcing facility; section 503B applies to compounding within an outsourcing facility. FDA also says one section 503A condition is receipt of a valid patient-specific prescription, while section 503B outsourcing facilities may distribute compounded drugs either pursuant to a patient-specific prescription or in response to a health care provider's order that is not for an identified individual patient, such as office stock. Research-use products and gray-market peptides are outside the consumer medicine evidence chain and should not be treated as substitutes for labeled drugs.
What FDA is warning about now
FDA's current unapproved-GLP-1 page describes risks from products that have not been reviewed for safety, effectiveness, or quality, including fraudulent labels, dosing-error reports, adverse-event reports, and semaglutide salt forms such as semaglutide sodium or semaglutide acetate. FDA says those salt forms are different active ingredients from the approved drugs and that it is not aware of a lawful basis for using them in compounding.
Label evidence has boundaries
DailyMed and openFDA label records can support claims about the specific FDA-approved product they name, including indications, warnings, contraindications, adverse reactions, ingredient form, route, dosage form, and how the manufacturer describes the product. They do not prove that a compounded preparation, a salt form, a counterfeit-labeled product, or a research-use vial has the same safety, effectiveness, quality, or dosing reliability.
The short version
FDA-approved GLP-1 products such as Wegovy, Ozempic, Zepbound, and Mounjaro have product-specific labels, manufacturing controls, adverse-event monitoring, and clinical-trial evidence tied to exact products and indications. Compounded or otherwise unapproved GLP-1 versions do not go through FDA review for safety, effectiveness, or quality before marketing.
That means branded-product trial results should not be automatically applied to compounded products, salt forms, research-use peptides, online copies, or any product whose ingredient form, quality system, and label are not the same as the approved medicine.
Four categories readers should not blur together
Approved branded products are medicines with FDA-reviewed labeling for specific indications. Off-label use is a clinician-directed use of an approved product outside a labeled indication; it is not the same thing as an unapproved copy. Compounded products are not FDA-approved. FDA describes section 503A as applying to compounding by a licensed pharmacist within a state-licensed pharmacy or federal facility, or by a licensed physician, that is not a registered outsourcing facility; section 503B applies to compounding within an outsourcing facility. FDA also says one section 503A condition is receipt of a valid patient-specific prescription, while section 503B outsourcing facilities may distribute compounded drugs either pursuant to a patient-specific prescription or in response to a health care provider's order that is not for an identified individual patient, such as office stock. Research-use products and gray-market peptides are outside the consumer medicine evidence chain and should not be treated as substitutes for labeled drugs.
- Approved product: use the exact FDA/DailyMed label and trial population for claims.
- Off-label context: separate the approved product from the unapproved use being discussed.
- Compounded context: do not copy-paste branded trial outcomes or safety assumptions.
- Research-use context: do not treat mechanism or animal/cell evidence as human outcome proof.
What FDA is warning about now
FDA's current unapproved-GLP-1 page describes risks from products that have not been reviewed for safety, effectiveness, or quality, including fraudulent labels, dosing-error reports, adverse-event reports, and semaglutide salt forms such as semaglutide sodium or semaglutide acetate. FDA says those salt forms are different active ingredients from the approved drugs and that it is not aware of a lawful basis for using them in compounding.
The same FDA page reports adverse events associated with compounded semaglutide and tirzepatide and notes that adverse events are likely underreported because state-licensed pharmacies that are not outsourcing facilities are not federally required to submit those reports. This is a signal to keep claims cautious, not a basis for ranking products or giving purchase advice.
Label evidence has boundaries
DailyMed and openFDA label records can support claims about the specific FDA-approved product they name, including indications, warnings, contraindications, adverse reactions, ingredient form, route, dosage form, and how the manufacturer describes the product. They do not prove that a compounded preparation, a salt form, a counterfeit-labeled product, or a research-use vial has the same safety, effectiveness, quality, or dosing reliability.
Published semaglutide and tirzepatide trials are useful for understanding the branded evidence base. They should be introduced as approved-product or trial-population evidence, not as proof that an unapproved version will produce the same benefit-risk profile.
Safer questions, not access instructions
If a reader hears about a non-standard GLP-1 route, the safer move is not to search for a supplier or copy a protocol. It is to ask a licensed clinician to explain the exact product category, whether an FDA-approved option can meet the medical need, what evidence applies to that exact situation, what monitoring is planned, and what safety red flags should be escalated.
- What exact product category is being discussed: approved branded, off-label approved product, compounded, investigational, or research-use?
- Which claims come from the approved label, which come from published trials, and which are only assumptions?
- What personal risk factors or symptoms would change the plan or require urgent care?
- What happens if access, shortage status, enforcement context, or side effects change?
Our editorial boundary
The Glow Diary can explain regulator concerns, evidence-transfer limits, label boundaries, and clinician questions. It does not recommend compounded GLP-1 products, identify suppliers, compare pharmacies, provide coupons or prices, publish dosing protocols, or tell readers how to obtain medication.
Sources and further reading
These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.